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Targeting of immunoglobulin E (IgE) represents an interesting approach for the treatment of
allergic disorders. A high-afﬁnity monoclonal anti-IgE antibody, ligelizumab, has recently been
developed to overcome some of the limitations associated with the clinical use of the ther-
apeutic anti-IgE antibody, omalizumab. Here, we determine the molecular binding proﬁle and
functional modes-of-action of ligelizumab. We solve the crystal structure of ligelizumab
bound to IgE, and report epitope differences between ligelizumab and omalizumab that
contribute to their qualitatively distinct IgE-receptor inhibition proﬁles. While ligelizumab
shows superior inhibition of IgE binding to FcεRI, basophil activation, IgE production by B cells
and passive systemic anaphylaxis in an in vivo mouse model, ligelizumab is less potent in
inhibiting IgE:CD23 interactions than omalizumab. Our data thus provide a structural and
mechanistic foundation for understanding the efﬁcient suppression of FcεRI-dependent
allergic reactions by ligelizumab in vitro as well as in vivo.
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As a key driver in the development and manifestation ofhypersensitivity reactions against normally non-hazardous substances, immunoglobulin E (IgE) has
become a major target of therapeutic intervention strategies1–3.
IgE is known to interact with two major receptors, FcεRI and
CD23/FcεRII4, which are involved in different immunological
processes5. Binding of allergen-speciﬁc IgE to FcεRI expressed on
immunological effector cells including basophils and mast cells
occurs with high afﬁnity (KD 10−10 M). This interaction occurs
via two asymmetric binding sites on the receptor and is stabilized
through the induction of a conformational change in IgE6–8.
Exposure to allergens induces cross-linking of IgE-bound FcεRI
resulting in immediate activation of allergic effector cells, which
culminates in cellular degranulation and the release of vasoactive
and pro-inﬂammatory mediators9.
While this FcεRI-dependent cellular degranulation process
accounts for immediate hypersensitivity reactions and the induction
of clinical allergy symptoms, the interaction of IgE with CD23 has
been reported to be involved in antigen presentation, the transport
of antigens across airway and intestinal epithelial barriers and the
regulation of IgE synthesis10–13. Binding of IgE to monomeric
CD23 is of low afﬁnity (KD 10−6–10−7M)14. However, cell surface
CD23 is prone to oligomerization leading to enhanced binding of
IgE:allergen complexes on antigen presenting cells10,15. Further-
more, various studies have provided evidence that IgE binding to
CD23 on B-cells negatively regulates IgE synthesis11,13,16.
Over the last decades, various anti-IgE inhibitors including
antibodies17–22, DARPin® proteins23–25 and nanobodies26,27 have
been generated and tested in pre-clinical studies. To date, the
monoclonal antibody omalizumab (Xolair®) represents the only
licensed anti-IgE compound for clinical use. Omalizumab shows
remarkable therapeutic efﬁcacy in allergic asthma and chronic
spontaneous urticaria17,28,29. Recently, a next-generation high-
afﬁnity anti-IgE monoclonal antibody (ligelizumab; QGE031) has
been developed with the intention of overcoming some of the
limitations associated with omalizumab18,30.
Given its current status as a potential anti-IgE therapeutic and
successor to omalizumab, we sought to investigate the IgE binding
characteristics of ligelizumab and its modes-of-action. Here, we
report the crystal structure of ligelizumab bound to IgE, revealing
that it recognizes a distinct IgE epitope only partially overlapping
with that of omalizumab. Ligelizumab interacts across the IgE-Fc
dimer and favors the recognition of IgE in an open conformation
different from its FcεRI- or CD23-bound conformations. More-
over, it binds IgE with signiﬁcantly higher afﬁnity than omalizu-
mab and shows a correspondingly enhanced inhibition of IgE
binding to FcεRI and basophil activation. In contrast and despite
its higher afﬁnity for IgE, ligelizumab is inferior to omalizumab in
preventing IgE binding to CD23. Structural analysis indicates that
differences in the ligelizumab epitope and spatial orientation on
IgE contribute to this differential inhibition. We further observe
that ligelizumab features the ability to reduce IgE production in
peripheral blood mononuclear cell (PBMC) cultures, a process
which may be mediated by its ability to bind IgE:CD23 complexes
at the surface of B-cells. Together, our data provide a structural and
mechanistic foundation for understanding why ligelizumab exerts a
qualitatively and functionally distinct inhibition proﬁle from
omalizumab and is superior in suppressing FcεRI-dependent
allergic reactions in vitro, in a passive systemic anaphylaxis
mouse model in vivo and in clinical studies with chronic sponta-
neous urticaria patients31.
Results
Ligelizumab binding characteristics. A central mechanism of
therapeutic anti-IgE antibodies is the neutralization of free serum
IgE. The binding afﬁnity for IgE may therefore be a major
determinant of clinical efﬁcacy. To assess binding kinetics of
ligelizumab to human IgE, we performed surface plasmon reso-
nance (SPR) measurements. Human monoclonal Sus11-IgE was
displayed on the chip surface via the non-competitive anti-IgE
capture antibody Le27 (ref. 32). Different concentrations of lige-
lizumab IgG as well as its F(ab′)2 and Fab fragments were mea-
sured in consecutive cycles on surface displayed IgE (Fig. 1a and
Supplementary Fig. 1a, b). As a comparison, the same measure-
ments were performed with the therapeutic anti-IgE antibody
omalizumab IgG and its F(ab′)2 or Fab fragments (Fig. 1b and
Supplementary Fig. 1c, d). The individual association (ka) and
dissociation (kd) constants were calculated using a 1:1 binding
langmuir curve ﬁtting model (Table 1, Fig. 1a, b and Supple-
mentary Fig. 1a–d). With a KD of 35 pM, the interaction of
ligelizumab Fab with IgE was ~88-fold stronger than the binding
of omalizumab Fab. While the measurements of the association
constants for ligelizumab or omalizumab Fab revealed rather
small differences, ligelizumab featured an ~15-times lower dis-
sociation rate. The difference in afﬁnity was further conﬁrmed by
dose-dependent titration of ligelizumab or omalizumab IgG and
its F(ab′)2 or Fab fragments on surface displayed IgE in a titration
ELISA (Supplementary Fig. 1e–g).
IgE is a ﬂexible protein, which undergoes conformational
rearrangements depending on its interaction partner33. Various
studies have demonstrated that IgE binds FcεRIα in an open Cε3
domain conformation6, while CD23-bound IgE adopts a closed
Cε3 conformational state34 and that these receptor interactions
are mutually exclusive35. We have previously engineered an IgE-
Fc3-4 variant (C335) that is trapped in a closed FcεRIα
incompatible conformation36, while the wild-type IgE-Fc3-4
(C328) can adopt an open FcεRIα-binding state (Fig. 1c). To
assess whether ligelizumab features binding preference for one
of these conformational states, we measured its interaction
with C328 or C335 IgE-Fc3-4 by SPR. Ligelizumab recognized the
wild-type C328 IgE-Fc3-4 variant with ~60-fold higher afﬁnity
(Fig. 1d, e and Supplementary Table 1). In contrast, omalizumab
showed similar binding to both conformations (Table 1 and
Fig. 1g, h). These ﬁndings were further conﬁrmed by ELISA, in
which ligelizumab again showed preferential binding to wild-type
C328 IgE-Fc3-4, while omalizumab did not discriminate between
the two conformational variants (Fig. 1f, i).
To obtain structural insight into the ligelizumab binding
epitope on IgE, we solved the crystal structure of the C328 IgE-
Fc3-4 fragment bound to the single chain fragment variable (scFv)
construct of ligelizumab to a resolution of 3.65 Å (Supplementary
Table 2). The crystal structure (PDB ID: 6UQR) shows two
ligelizumab scFvs binding across the IgE dimer, with each scFv
forming interactions with both Cε3 domains (Fig. 1j, k). The
majority of the ligelizumab interaction is mediated through VH
domain interactions with one of the Cε3 domains, with a total
buried surface area of ~1200 Å2. This primary contact is formed
by ~15 residues of the ligelizumab VH domain with heavy chain
complementary determining region 1 (HCDR1) residues W31,
Y32 and W33 forming key contacts at the center of the interface
(Fig. 1l, m). By comparison, HCDR3 extends along the inner face
of the Cε3 domain and makes more peripheral contacts with IgE.
The ligelizumb VH domain contacts 21 residues of the IgE,
centered around Q417, R419 and M430 (Fig. 1l, m). Ligelizumab
contacts with the second Cε3 domain appear relatively minor,
burying only ~170 Å2 of accessible surface area and involving
only 6 residues in VL with 4 residues in IgE. In this cross-dimer
contact, ligelizumab VL residues interact with the IgE loop
containing its conserved N-linked glycosylation site at residue
394. These contacts likely contribute little to overall ligelizumab
afﬁnity, but the cross-dimer interactions would restrict the
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conformations accessible to the Cε3 domain. The structural data
indicate that in the ligelizumab complex, the IgE Cε3 dimer
appears more open, with a V336–V336 distance of 17 Å as
compared to ~12 Å in the constrained C335 IgE-Fc3-4 variant and
consistent with its reduced afﬁnity for this C335 mutant.
Ligelizumab and omalizumab clearly bind to different epitope
structures on the IgE-Fc dimer; however, they share a signiﬁcant
overlapping region (Fig. 1n, o). In addition, the angle of binding
of the two antibodies relative to the IgE-Fc domain also differs,
affecting their respective functions in receptor inhibition.
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Characterization of the ligelizumab IgE inhibition proﬁle.
Given that ligelizumab has superior afﬁnity for IgE than omali-
zumab, we aimed to compare their potency in preventing IgE
binding to FcεRIα using ELISA and cell-based assays. For ELISA
assays, we used a Sus11-IgE concentration (0.78 nM) at the
midpoint of its binding titration with FcεRIα, which falls within
physiological IgE concentrations (Supplementary Fig. 2a), to
investigate dose-dependent inhibition of IgE-binding to FcεRIα
by ligelizumab or omalizumab IgG (Fig. 2a). The results show
that ligelizumab inhibits IgE-binding to FcεRIα with a 20-fold
higher potency than omalizumab. We also measured ligelizumab-
and omalizumab-mediated inhibition of IgE-binding to isolated
human primary basophils by ﬂow cytometry. These cells express
high levels of CD123, CD193 and carry FcεRIα-bound IgE on
their surface (Fig. 2b). After removing endogenous IgE from the
isolated basophils25, we used a physiologically relevant con-
centration of 2 nM of JW8-IgE (Supplementary Fig. 2b) in the
inhibition assay. IgE was pre-incubated with varying concentra-
tions of ligelizumab or omalizumab IgG (Fig. 2c). Ligelizumab
blocked IgE binding with greater potency, consistent with its
higher afﬁnity and with the ELISA results.
Given the difference in their binding epitopes on IgE, we
further explored the ability of ligelizumab and omalizumab to
inhibit IgE-binding to CD23. Due to the low afﬁnity of the CD23
interaction, pre-formed IgE:antigen complexes were used in this
ELISA. A concentration of 70 nM IgE:antigen complexes
(Supplementary Fig. 2c) was incubated with physiologically
relevant amounts of ligelizumab or omalizumab IgG prior to
the addition to immobilized CD23. Interestingly, despite its
higher afﬁnity for IgE, ligelizumab showed a fourfold weaker
inhibition of IgE-binding to CD23, as compared to omalizumab
(Fig. 2d). To further evaluate CD23 competition on cells, we
measured ligelizumab- and omalizumab-mediated inhibition of
IgE-binding to CD23 by ﬂow cytometry using the CD19-/CD23-
expressing leukemia B-cell line RPMI8866 (Fig. 2e). A
physiologically relevant IgE concentration of 12.5 nM (Supple-
mentary Fig. 2d) was pre-incubated with ligelizumab or
omalizumab IgG in varying concentrations. In agreement with
the ELISA data, we observed weaker inhibition of IgE-binding to
CD23 on RPMI8866 cells with ligelizumab than with omalizumab
(Fig. 2f). Thus, the two anti-IgE antibodies reveal a qualitatively
distinct inhibition proﬁle for the two IgE receptor pathways with
ligelizumab being more potent and more selective for inhibition
of IgE binding to FcεRI.
Previous studies have reported that human BDCA1+ dendritic
cells (DCs) constitutively express surface FcεRI resulting in rapid
binding and endocytosis of serum IgE37. The mechanism of
FcεRI-mediated IgE:antigen complex uptake and presentation by
DCs has further been proposed to promote Th2 immune
responses38,39. To assess the effect of ligelizumab and omalizu-
mab on IgE-binding and IgE:antigen complex internalization
with DCs, we isolated human BDCA1+ DCs from whole-blood
donations (Supplementary Fig. 3a) and assessed IgE binding and
internalization in the presence of ligelizumab and omalizumab. In
contrast to the results obtained with basophils, both anti-IgE
antibodies dose-dependently inhibited binding of IgE with the
same efﬁcacy (Supplementary Fig. 3b). By analyzing IgE receptors
expression on BDCA1+ DCs, we found evidence for co-
expression of FcεRIα and CD23, which explains the lack of
superior inhibition of ligelizumab in this experimental setup
(Supplementary Fig. 3c). Next, we compared the uptake of IgE:
antigen complexes of basophils and BDCA1+ DCs. Maximal
internalization was reached after 4 h of incubation for basophils
and 8 h for DCs as detected by pH-sensitive IgE staining
(Supplementary Fig. 3d). In line with previous results, ligelizumab
inhibited the IgE:antigen complex uptake in basophils more
efﬁciently than omalizumab (Supplementary Fig. 3e). Interest-
ingly, only F(ab′)2 fragments prevented complex internalization
in DCs, whereas the full-length antibodies increased the uptake
presumably through engagement of Fcγ-receptors that are
present on the surface of these cells (Supplementary Fig. 3f).
The crystal structure of the ligelizumab svFv:IgE-Fc3-4 complex
provides detailed insights into its ability to inhibit FcεRI and
CD23 binding (Fig. 2g–k). Views of the IgE:ligelizumab and IgE:
FcεRIα complexes along the IgE dimer axis show that the two
ligelizumab scFvs mimic the arrangements of FcεRI and IgE Cε2
domains on either side of the central pair of Cε3 domains (Fig. 2g,
h). Therefore, at least three mechanisms could contribute to the
ability of ligelizumab to efﬁciently block FcεRI binding. First, one
of the ligelizumab scFvs occupies a largely overlapping volume
with FcεRIα, indicating that substantial steric conﬂicts between
ligelizumab and FcεRIα prevent their simultaneous binding
(Fig. 2g, h). Second, the interaction footprints of ligelizumab
Fig. 1 Binding kinetics of ligelizumab or omalizumab on recombinant human IgE. a, b Association and dissociation of ligelizumab (a) and omalizumab (b)
Fab fragments to human recombinant Sus11-IgE by SPR. Each color refers to an individual measurement cycle. Curves were ﬁtted (black dashed) using a 1:1
langmuir binding model. c Wildtype C328 and mutant C335 IgE-Fc3-4. d, e Binding of wt C328 IgE-Fc3-4 (d) and mut C335 IgE-Fc3-4 variants (e) to
ligelizumab IgG by SPR. f Binding of wt C328 IgE-Fc3-4 or mut C335 IgE-Fc3-4 to ligelizumab IgG by ELISA (technical duplicates as mean ± SEM).
g, h Binding of wt C328 IgE-Fc3-4 (g) and mut C335 IgE-Fc3-4 (h) to omalizumab IgG by SPR. i Binding of wt C328 IgE-Fc3-4 or mut C335 IgE-Fc3-4 to
omalizumab IgG by ELISA (technical duplicates as mean ± SEM). j–m Crystal structure of ligelizumab single chain Fv (scFV) bound to wt C328 IgE-Fc3-4
(PDB ID: 6UQR). IgE-Fc3-4 dimer in surface representation (white and light gray). Ligelizumab epitope residues shown in blue. The ligelizumab scFv is
shown in cartoon format (light orange and wheat). 90˚ rotations with perpendicular (j) and parallel (k) view to IgE-Fc twofold axis. l, m Contact interface
between ligelizumab VH and VL CDR loops with the two IgE Cε3 domains. l Orientation along the IgE twofold axis. m Orientation from the side of the VH:
IgE-Fc interaction. Ligelizumab VH domain interaction is centered around IgE residues R419, M430 and Q417. Ligelizumab residue W31 packs into a pocket
on IgE, with additional HCDR1 residues (Y32 and W33) forming interactions that straddle the central R419/M430/Q417 site. Interactions of the VL domain
with IgE are limited and located adjacent to residue N394. n Structure of omalizumab bound to IgE-Fc (PDB ID: 5HYS41) oriented as in k. Omalizumab is
shown in ribbon format with heavy chains (violet) and light chains (magenta). IgE is shown in surface format with interface residues (magenta). o Overlap
of ligelizumab and omalizumab epitopes. Residues unique to omalizumab interactions (magenta) and unique to ligelizumab are (blue) and those that
interact with both antibodies (violet) are shown. Source data are provided as Source Data ﬁle.
Table 1 Binding kinetics of ligelizumab and omalizumab
variants for human IgE.
Anti-IgE antibody Association ka
(M−1s−1)
Dissociation kd
(s−1)
Afﬁnity
KD (pM)
Ligelizumab IgG 1.8 × 106 3.3 × 10−5 17.8
Omalizumab IgG 9.1 × 105 2.4 × 10−3 2659
Ligelizumab F(ab′)2 4.2 × 106 5.1 × 10−5 12.1
Omalizumab F(ab′)2 8.7 × 105 2.6 × 10−3 2998
Ligelizumab Fab 9.2 × 106 3.2 × 10−4 35.0
Omalizumab Fab 1.5 × 106 4.6 × 10−3 3090
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Fig. 2 Inhibition of IgE binding to FcεRIα and CD23 by ligelizumab or omalizumab. a Inhibition of IgE binding to FcεRIα through ligelizumab or
omalizumab IgG by ELISA. b Isolated primary human blood basophils are gated as SSClow, FSClow, CD123+, CD193+ double-positive cells. A histogram of
basophil surface IgE levels before (black line) and after desensitization with 5 µM disruptive-anti-IgE DARPin® bi53_79 (gray line) and after resensitization
with recombinant human JW8-IgE (dashed gray line) is shown. c Inhibition of IgE binding to FcεRIα on isolated bi53_79-treated basophils by ligelizumab or
omalizumab IgG. Binding curves were ﬁtted using a non-linear regression model. d Inhibition of IgE:antigen complex binding to CD23 by ligelizumab or
omalizumab IgG by ELISA. e Surface expression of CD23 on RPMI8866 cells by ﬂow cytometry. f Inhibition of IgE binding to RPMI8866 cells by ligelizumab
or omalizumab IgG. Binding curves (technical duplicates as mean ± SEM) were ﬁtted using a non-linear regression model. g–i Ligelizumab sterically blocks
FcεRI binding overlaps with receptor-binding residues in both IgE subunits. g Ligelizumab complex in surface representation with the view along the IgE
twofold axis (PDB ID: 6UQR). VH and VL domains are (light orange and wheat) and IgE subunits (white and light gray) are shown. h The structure of IgE-
Fc2-4 with FcεRIα (PDB ID: 2Y7Q53) in surface format, with the receptor (salmon) and IgE chains (white and light gray). One ligelizumab scFv sterically
blocks receptor binding, while second scFv overlaps the position of the IgE Cε2 domains. i Overlap of IgE residues involved in both FcεRI and ligelizumab
binding. IgE-Fc3-4 in a surface representation is shown with common contacts shared by ligelizumab and FcεRIα (magenta), FcεRIα-speciﬁc contacts (red)
and ligelizumab-speciﬁc (blue). j Structure of CD23:IgE-Fc3-4 complex (PDB ID: 4EZM57). IgE in surface representation with CD23 (light green). k IgE
binding sites for CD23 have minimal overlap with ligelizumab epitope. IgE residues involved solely in ligelizumab binding (blue), those involved only in
CD23 binding (green) and the overlapping contact residues (cyan) are shown. a, c, d, f Data shown for technical duplicates as mean ± SEM. Source data are
provided as Source Data ﬁle.
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and FcεRIα on IgE show that both ligands share a number of
identical binding residues on IgE (Fig. 2i), indicating potential for
direct, though limited, competition for subsite binding. Third, the
binding of ligelizumab across the IgE dimer restricts the
arrangement of the Cε3 domains into a conformation that is
incompatible with FcεRI binding (Fig. 2g, h). Furthermore,
ligelizumab binding to intact IgE would also displace Cε2
domains, generating a more linear structure that might interfere
with FcεRIα binding40.
CD23 interacts with IgE-Fc at the hinge region between Cε3
and Cε4 domains (Fig. 2j), favoring a closed conformation of Cε3
domains34. Comparison of the CD23 and ligelizumab interaction
sites on IgE indicates relatively minor overlap between binding
sites of these two IgE ligands (Fig. 2k). Furthermore, the
orientation of the ligelizumab VHVL domains on IgE (Fig. 2g)
indicates that the ligelizumab Fab would project away from the
IgE and would not sterically overlap bound CD23, suggesting that
competition for IgE surface subsites and the stabilization of an
open Cε3 conformation would be the primary mechanism of
CD23 inhibition. In contrast, omalizumab-mediated inhibition of
CD23 binding to IgE is effected by both substantial steric overlap
between omalizumab and CD23, and through direct competition
for IgE-binding residues by the omalizumab heavy chain41.
Comparisons of the omalizumab and ligelizumab complexes with
IgE (Fig. 1j–o and Supplementary Fig. 4) show that the antibody
binding footprints and orientations contribute to the signiﬁcant
differences in their relative abilities to inhibit CD23 or FcεRIα
binding.
Determination of ability to disrupt FcεRI:IgE complexes. We
previously reported that omalizumab in addition to its ability to
neutralize free serum IgE accelerates IgE dissociation from the
surface of FcεRIα-expressing cells at concentrations well above its
KD24,25. To test whether ligelizumab shares this additional mode
of action, we assessed its ability to actively remove FcεRIα-bound
IgE. Using SPR, we pre-complexed monoclonal human Sus11-IgE
with immobilized recombinant human FcεRIα. Subsequently,
0.25–1 µM ligelizumab IgGs were continuously added for 8 h to
FcεRIα-bound IgE. No dissociation above buffer baseline was
observed for any of the ligelizumab concentrations (Fig. 3a). In
contrast, omalizumab IgG showed dose-dependent removal of
IgE from FcεRIα at concentrations ≤1 µM as judged by the
steadily declining surface signal (Fig. 3b). Additionally, we eval-
uated ligelizumab- and omalizumab-mediated IgE dissociation
from FcεRIα on the cell surface of isolated primary human
basophils. Using the same concentrations of anti-IgE antibodies
and antibody fragments, we quantiﬁed IgE cell surface levels after
3 and 6 days of cell culture in the presence of the respective anti-
IgE antibody (Fig. 3c). Again, omalizumab but not ligelizumab
treatment resulted in dose-dependent removal of surface IgE.
We have previously observed that omalizumab can form stable
ternary complexes with FcεRIα-bound IgE-Fc3–4 fragments
without removing them from the receptor25,41. This is due to
the exposure of one of the omalizumab epitopes that is buried by
Cε2 domains in the intact IgE. We therefore assessed whether
ligelizumab exhibits similar binding behavior using SPR. IgE-
Fc3–4 was pre-complexed with immobilized FcεRIα and ligelizu-
mab IgG was subsequently added. Interestingly, we observed
rapid disruption of IgE-Fc3–4:FcεRIα complexes (Fig. 3d). This
was not the case for omalizumab IgG, which showed pronounced
binding to IgE-Fc3–4:FcεRIα complexes without obvious disrup-
tive activity (Fig. 3e). The anti-IgE antibody Le2732, which binds
non-competitively to a Cε4 domain epitope and was used as a
control, also recognized FcεRIα-bound IgE-Fc3–4 in a dose-
dependent manner (Fig. 3f).
The structure of the IgE-Fc3–4:ligelizumab scFv complex
suggests a conformational mechanism to explain the ability of
ligelizumab to disrupt these preformed IgE-Fc3–4:FcεRIα com-
plexes. Superposition of the ligelizumab and FcεRI complex
structures through the Cε3 domain that forms the majority of the
exposed ligelizumab epitope shows signiﬁcantly different arrange-
ments of the second Cε3 domain (Fig. 3g, h). While FcεRI
binding requires an asymmetric arrangement of the two Cε3
domains, ligelizumab binding restricts the position of the second
Cε3 domain, causing an overall shift in FcεRI-binding loops
of ~11 Å (Fig. 3g, h). Ligelizumab binding forces the Cε3 domains
into a more symmetrical arrangement that closely aligns with the
IgE dimer twofold axis deﬁned by the Cε4 domains and that is
incompatible with FcεRI binding. The ability of ligelizumab to
bind and dissociate the IgE-Fc3-4:FcεRI complexes suggests that
the complex can dynamically access conformational states in
which the secondary Cε3 domain does not sterically block
ligelizumab binding.
To further investigate whether ligelizumab accelerates dis-
sociation of FcεRI-bound IgE-Fc3–4 on allergic effector cells, we
isolated primary human basophils, removed endogenous IgE
from the cell surface using a disruptive anti-IgE DARPin®
protein, re-sensitized the cells with either 100 nM JW8-IgE or
C328 IgE-Fc3–4 and subsequently added ligelizumab or omalizu-
mab IgG. As expected, the IgE surface levels of JW8-IgE re-
sensitized cells did not show any decrease upon treatment with
either of the two anti-IgE antibodies at these concentrations as
measured by ﬂow cytometry (Fig. 3i). Additionally, we analyzed
the activation status of these cells by measuring CD63 surface
levels. In line with our SPR data suggesting the inability of
ligelizumab or omalizumab to recognize FcεRI-bound full length
IgE (Supplementary Fig. 5a–e), no activation was observed for
either of the two anti-IgE antibodies (Fig. 3j). Re-sensitizing cells
with IgE-Fc3–4, instead of intact IgE, revealed that ligelizumab but
not omalizumab treatment resulted in a dose-dependent reduc-
tion of surface IgE-Fc3–4 levels on cells (Fig. 3k). Strikingly and in
line with the corresponding binding data, we found that
omalizumab but not ligelizumab can activate basophils re-
sensitized with IgE-Fc3–4 in a dose-dependent manner (Fig. 3l).
Engagement of CD23:IgE complexes. CD23 is known to play an
important role in enhancing IgE-mediated allergen presentation
by antigen presenting cells and in the regulation of IgE produc-
tion by B-cells5. Various studies have demonstrated that com-
pounds targeting CD23 or CD23-bound IgE on B-cells can inhibit
IgE production22,42–44. Since the crystal structure of ligelizumab
with IgE-Fc3–4 showed only a minor overlap with CD23-binding
residues, we assessed whether ligelizumab might also be able to
bind IgE:CD23 complexes. For this purpose, we performed SPR
experiments in which JW8-IgE was pre-complexed with immo-
bilized CD23 on the chip surface (Fig. 4a). Upon subsequent
injection of different ligelizumab or omalizumab concentrations,
the IgE binding signal immediately decreased, indicating that IgE
is displaced from CD23 by both anti-IgE antibodies (Fig. 4b). To
check whether ligelizumab or omalizumab IgG formed ternary
complexes with the remaining CD23-bound IgE on the chip
surface, we additionally injected a polyclonal anti-IgG antibody.
While CD23:IgE:ligelizumab complexation could be revealed by
anti-IgG antibody, only minor signal was detectable with omali-
zumab (Fig. 4c). To conﬁrm these results on a cellular level,
CD23-expressing RPMI8866 cells were pre-sensitized with 12.5
nM JW8-IgE, washed and subsequently treated with an equimolar
concentration of ligelizumab, omalizumab or a control IgG. Both
anti-IgE treatments resulted in a reduction of surface IgE levels as
measured by quantifying remaining CD23-bound IgE (Fig. 4d).
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In line with the increased afﬁnity of ligelizumab for free IgE, it
showed more pronounced reduction of CD23-bound IgE cell
surface levels. Nevertheless, we detected more prominent binding
of ligelizumab to IgE remaining on the cell surface (Fig. 4e),
which is in line with the SPR results. Additionally, when CD23
was blocked with an anti-CD23 compound prior to sensitization
of the cells with JW8-IgE, almost no surface IgE could be detected
and only minor binding of ligelizumab was observed, providing
further evidence that ligelizumab binding to the
RPMI8866 surface is dependent on the presence of CD23:IgE
complexes. By adding 12.5 nM JW8-IgE and an equimolar
amount of ligelizumab to RPMI8866 cells, roughly one-third of
the cells showed ligelizumab-binding on their surface (Fig. 4f, g).
We additionally performed image stream ﬂow cytometry analysis
with the same experimental setup to provide direct visual evi-
dence for ligelizumab-binding on IgE-sensitized RPMI8866 cells.
All conditions showed clear staining for CD23 and IgE.
Ligelizumab-treated cells were additionally positive for IgG
staining (Fig. 4h) and showed clustering of IgE, indicating co-
aggregation of CD23-bound IgE by ligelizumab (Fig. 4i).
Co-localization analysis of IgE and IgG staining in ligelizumab-
treated cells resulted in a 73.7% overlapping signal, while Oma-
lizumab again showed only very weak binding and negligible
co-localization.
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Assessment of functional efﬁcacy. Given the differences in
binding afﬁnities, epitopes and receptor competition proﬁles of
ligelizumab and omalizumab, the two anti-IgE antibodies were
further compared in functional assays. First, we assessed their
inhibitory efﬁcacy in a basophil activation test. To do so, endo-
genous IgE was removed from isolated primary human basophils
using a disruptive anti-IgE DARPin® protein and cells were
reloaded with different concentrations of NIP-speciﬁc JW8-IgE.
Upon challenge of the resensitized cells with NIP7-BSA antigen,
basophil degranulation was quantiﬁed by measuring cell surface
CD63 levels using ﬂow cytometry (Fig. 5a). IgE dose-dependent
basophil activation was observed at a constant antigen con-
centration of 100 ng/ml NIP7-BSA (Supplementary Fig. 2e). A
concentration of 0.68 nM JW8-IgE was subsequently used for
pre-incubation of ligelizumab or omalizumab IgG with JW8-IgE
prior to re-sensitization of the cells. Antigen stimulation with
NIP7-BSA showed dose-dependent inhibition of basophil acti-
vation with both anti-IgE antibodies, whereby ligelizumab was
more potent than omalizumab (Fig. 5b), consistent with the
greater inhibitory activity of ligelizumab in blocking the IgE:
FcεRIα interaction.
To further substantiate these ﬁndings in a representative
FcεRI-dependent in vivo allergy model, a passive systemic
anaphylaxis test was performed using mice transgenic for the
human FcεRIα (huFcεRIα tg)45. These mice can be passively
sensitized with human antigen-speciﬁc IgE and challenged with
the corresponding antigen to induce a systemic anaphylaxis
(PSA). The mice were pre-treated with 10 µg of anti-IgE antibody
or PBS prior to sensitization with 20 µg of NIP-speciﬁc JW8-IgE
(Fig. 5c). The following day the mice were challenged with 200 µg
of NIP20-BSA and the body core temperature was measured.
While mice treated with ligelizumab were completely protected
against antigen-induced systemic anaphylaxis, omalizumab-
treated animals showed only partial protection (Fig. 5d). These
data reﬂect the degree of remaining IgE found on mast cells in
peritoneal lavages from the mice, as identiﬁed by CD45+, c-kit+,
CD200R3+ cells by ﬂow cytometry (Fig. 5e). Thus, the cell surface
IgE levels closely correlate with the functional results of the PSA
(Fig. 5f), with the ligelizumab-treated mice displaying only low
levels of IgE on their peritoneal mast cells. These data further
demonstrate the improved activity of ligelizumab in neutralizing
free IgE and inhibiting FcεRI-dependent allergic reactions in vivo.
A recent study has provided strong evidence that ligelizumab
suppresses free serum IgE levels in humans for a signiﬁcantly
longer period-of-time than omalizumab after single dose injec-
tion18. To assess whether this effect might additionally be related
to ligelizumab-mediated inhibition of IgE production by B-cells,
we performed IgE ELISpot assays. In vitro IgE synthesis is
induced through incubation of isolated human PBMCs with IL-4
and anti-CD40 antibody46. Following this stimulation, we
determined the number of IgE-producing B-cells in the cell
culture by ELISpot assays and determined soluble IgE in culture
supernatants. Incubation of the PBMCs with ligelizumab resulted
in a signiﬁcant reduction of IgE-producing B-cells in PBMC
cultures, whereas the inhibition with omalizumab was less
pronounced (Fig. 5g, h). In line with this ﬁnding, soluble IgE in
culture supernatants of ligelizumab IgG or F(ab′)2-treated
PBMCs was signiﬁcantly decreased. Again, omalizumab IgG
showed less efﬁcient suppression and omalizumab F(ab′)2 had no
effect on IgE production, strongly suggesting that its suppression
is mediated via Fcγ-receptors. Interestingly, blocking of CD32b
(FcɣRIIb) in PBMC cultures completely abrogated omalizumab-
mediated suppression of IgE production, whereas ligelizumab-
mediated suppression remained unaltered. Together our results
demonstrate that the distinct IgE binding proﬁles and inhibition
properties of ligelizumab and omalizumab signiﬁcantly impact
their functional activity.
Discussion
Here, we compare structural and functional studies of two anti-
IgE antibodies, ligelizumab and omalizumab, to better understand
how their interactions with IgE impacts inhibitory mechanisms
and predicts their potential therapeutic beneﬁt. Ligelizumab and
omalizumab recognize distinct binding epitopes in the IgE Cε3
domain with some overlap and show different sensitivities to IgE
conformation. Therefore, the two anti-IgE antibodies display
different abilities to inhibit IgE interactions with FcεRI and CD23
and feature a qualitatively distinct inhibition proﬁle. Conse-
quently, they greatly differ in their functional activities in
blocking effector cell activation and IgE synthesis. While the
increased afﬁnity of ligelizumab for IgE explains superiority over
omalizumab regarding neutralization of free serum IgE, we have
identiﬁed an additional mode of action for ligelizumab through
the inhibition of IgE production, which may provide additional
therapeutic beneﬁt. We observe that ligelizumab is more efﬁcient
in suppressing FcεRI-dependent allergic reactions in an in vivo
model, while omalizumab may have advantages in blocking
antigen presentation and transport processes that are dependent
on IgE:CD23 interactions47,48. This balance of modulating IgE
interactions with its two receptors, along with their associated
functions, might have future consequences for the design of anti-
IgE therapeutics.
Our data conﬁrm that ligelizumab does not recognize FcεRIα-
bound IgE, which represents the critical safety requirement for
therapeutic anti-IgE antibodies. Interestingly, we observed that
ligelizumab efﬁciently removes IgE-Fc3-4 fragments from FcεRIα,
Fig. 3 Disruption of FcεRI:IgE complexes by ligelizumab or omalizumab. a and b Removal of FcεRI pre-complexed human recombinant Sus11-IgE by
ligelizumab (a) or omalizumab (b) IgG by SPR. Each color refers to an individual measurement cycle. Black line refers to baseline buffer control. Black
arrows indicate time of injection. c Isolated primary human basophils (n= 3 donors) were incubated for 3 or 6 days with indicated concentrations of
ligelizumab and omalizumab IgG. Levels of cell surface IgE were quantiﬁed by ﬂow cytometry (shown as mean ± SEM). d–f Interaction of ligelizumab or
omalizumab IgG with FcεRI-bound IgE-Fc3-4. d and e Binding of ligelizumab (d) and omalizumab (e) IgG to FcεRI pre-complexed human recombinant wt
C328 IgE-Fc3-4 by SPR. f The monoclonal anti-IgE antibody Le27 was included as positive control. Each color refers to an individual measurement. Black line
refers to baseline buffer control. Black arrows indicate the time of injection. g, h Comparisons of ligelizumab- and FcεRIα-IgE complex structures.
Complexes were superimposed using the primary VH-interacting Cε3 domain (corresponding to FcεRIα site 2), predominantly exposed in the IgE-Fc3-4
receptor-bound complex because of the absent Cε2 domains. A single ligelizumab (g) and FcεRIα (h) are shown in surface representations (light orange
and light blue). Two conformations of the IgE-Fc are shown. g Binding of ligelizumab restricts secondary Cε3 domain conformation, preferring displacement
(downward arrows). h FcεRIα binding to ligelizumab-stabilized Fc conformation is sterically blocked, requiring displacement of the Cε3 domain (upward
arrows). Surface IgE levels (i) and percentage of activated cells (j) of JW8-IgE sensitized primary human basophils incubated for 30min with ligelizumab or
omalizumab IgG. Surface IgE levels (k) and percentage of activated cells (l) of IgE-Fc3-4 sensitized primary human basophils incubated for 30min with
ligelizumab or omalizumab IgG. i–l Biological triplicates are displayed as mean ± SEM. Different conditions were compared to each other using two-way
ANOVA with Sidak’s multiple comparison. *P < 0.05, ***P < 0.001, ns = not signiﬁcant. Source data are provided as Source Data ﬁle.
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while omalizumab binds such complexes without disrupting
them25,41. Furthermore, we could show that the interaction of
omalizumab with such FcεRI-bound IgE-Fc3-4 fragments on
primary human basophils results in a dose-dependent degranu-
lation of the cells. Whether such IgE fragments exist in vivo in
certain situations remains to be investigated as well as whether
this could potentially explain rare systemic anaphylactic reactions
in roughly 0.2% of omalizumab-treated patients49. Ligelizumab
lacks the ability to cross-link FcεRIα-bound IgE-Fc3-4 fragments
and it will be interesting to see whether it shows a reduced risk of
anaphylaxis and an altered safety proﬁle as compared to
omalizumab.
We further observe that omalizumab inhibits IgE-binding to
CD23 more potently than ligelizumab, which could potentially
play an important role in the inhibition of IgE-mediated antigen
presentation and IgE-mediated transport across epithelial bar-
riers12,50. It has been shown that allergen-IgE complex-mediated
eosinophilic lung inﬂammation in mice was CD23 dependent48.
These ﬁndings might explain why ligelizumab treatment lacked
superior efﬁcacy in phase 2 clinical trials with severe asthma
patients compared to placebo and omalizumab (NCT02075008).
On the other hand, ligelizumab has the ability to recognize CD23-
bound IgE on B-cells and decreases IgE production in PBMC
cultures. This effect was not mediated by ADCC as F(ab′)2
fragments revealed a similar inhibition of IgE production. Our
data indicating that ligelizumab downregulates IgE production is
in line with the ﬁnding that single dose injection of ligelizumab
resulted in a signiﬁcantly longer suppression of free serum IgE
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Fig. 5 Inhibition of basophil activation and IgE production of B-cells by ligelizumab or omalizumab. a NIP7-BSA-mediated activation of isolated CD193+
primary human basophils resensitized with JW8-IgE using CD63 as degranulation marker by ﬂow cytometry. b Dose-dependent inhibition of primary
human basophil activation by pre-incubation of JW8-IgE with increasing concentrations of ligelizumab or omalizumab IgG and subsequent stimulation of
the cells with 100 ng/ml NIP7-BSA. Activation curves for technical duplicates were ﬁtted using a non-linear regression. c Experimental setup for the passive
systemic anaphylaxis assay with huFcεRIα tg mice. d Changes in body core temperature after antigen challenge for mice treated with ligelizumab,
omalizumab or PBS as control (n= 6 per group; pooled data from two individual experiments). Representative ﬂow plots (e) and absolute quantiﬁcation
(f) of ﬂow cytometric analysis of peritoneal mast cells after passive systemic anaphylaxis. g Representative pictures of IgE ELISpots with PBMCs from
human donors (n= 3 donors) that were stimulated with human recombinant IL-4 and anti-human CD40 antibody in the presence of a control IgG
antibody, ligelizumab or omalizumab IgG. h Quantiﬁcation of the number of IgE expressing cells. i Quantiﬁcation of soluble IgE in cell culture supernatants
of PBMCs from human subjects (n= 6 donors) that were stimulated with human recombinant IL-4 and anti-human CD40 antibody in the presence of
ligelizumab IgG or F(ab′)2 fragments, omalizumab IgG or F(ab′)2 fragments or a control IgG antibody. Data are shown as mean ± SEM. Different treatments
were compared relative to the untreated group using one-way ANOVA with Dunnett’s multiple comparison referenced to untreated controls. *P < 0.05,
***P < 0.001. Source data are provided as Source Data ﬁle.
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compared to omalizumab18. Further, our results strongly suggest
that the mechanism of ligelizumab suppression of IgE synthesis is
independent of Fcγ-receptor engagement but might rather be due
to its ability to bind and aggregate CD23:IgE complexes on the
surface of B-cells, which has not been observed for omalizumab.
In summary, the structural and mechanistic differences that we
have found between ligelizumab and omalizumab may have dif-
ferent impacts on FcεRI- and CD23-mediated pathways in
patients. Presently, it is concluded that ligelizumab has the
potential to be particularly efﬁcacious in diseases driven pre-
dominantly by FcεRI-dependent reactions, as observed in CSU31.
Methods
Recombinant proteins and antibodies. Ligelizumab as well as omalizumab
antibodies and fragments were produced and kindly provided by Novartis Pharma
AG (Basel, Switzerland). Sus11-IgE, JW8-IgE and the anaphylactogenic mono-
clonal anti-IgE antibody Le27 were purchased from NBS-C BioScience (Vienna,
Austria). Monoclonal anti-human CD40 antibody was purchased (Enzo Life Sci-
ences, NY, USA). Recombinant extracellular part of human FcεRIα as well as the
wild-type C328 IgE-Fc3-4 and the mutated C335 IgE-Fc3-4 were produced in our
laboratory36. Recombinant human CD23 was purchased (R&D Systems, Minnea-
polis, MN, USA). Recombinant human IL-3 and IL-4 were purchased from
Peprotec (London, UK). Cells were cultured in RPMI+/+ medium composed of
RPMI 1640 medium (Biochrome, Cambridge, UK) complemented with 10%
Hyclone FCS (Fisher Scientiﬁc, NH, USA), penicillin 100 U/ml, 100 µg/ml strep-
tomycin (100× penicillin/streptomycin, Merck, Darmstadt, Germany) and 10 mM
HEPES buffer (stock-solution 1M, Life Technologies, CA, USA). For ﬂow cyto-
metry, we used the following antibodies: anti-human IgE FITC (clone Ige21,
Thermo Fisher Scientiﬁc, MA, USA), monoclonal mouse anti-human FcεRIα APC
(clone AER-37, Thermo Fisher Scientiﬁc, MA, USA) and the appropriate isotype
controls monoclonal mouse IgG1, κ Isotype control FITC (Thermo Fisher Scien-
tiﬁc, MA, USA) and mouse IgG2b Isotype control APC (Thermo Fisher Scientiﬁc,
MA, USA), monoclonal rat anti-mouse CD200R FITC (clone OX-110, Bio-Rad,
CA, USA), monoclonal rat anti-mouse CD117 PE (clone 2B8, Thermo Fisher
Scientiﬁc, MA, USA), monoclonal mouse anti-human CD19 APC (clone HIB19,
BD Bioscience), monoclonal mouse anti-human CD23 FITC and PE (clone
EBVCS-5, Biolegend, CA, USA), monoclonal mouse anti-human Ig kappa light
chain PE (clone TB28-2, eBioscience, CA, USA). For basophil activation testing, the
anti-human CCR3 and anti-human CD63 antibody staining mix from the Flow
CAST® kit was used (Bühlmann Laboratories AG, Schönenbuch, CH).
Expression and puriﬁcation of IgE:ligelizumab complexes. A scFv codon-
optimized construct of ligelizumab was synthesized (Genscript) and cloned into
EcoRI/BamHI sites in the pTTVH8G vector for expression in mammalian HEK
293-6E cells (National Research Council, NRC, Canada). The scFv construct
consists of the VEGF signal sequence, the ligelizumab VH domain, a GTG
(GSGGG)3AS linker, the ligelizumab VL domain, a TEV cleavage site and linker to
a His8 tag (MNFLLSWVHWSLA LLLYLHHAKWSQAAPMAEGGGQNQVQLV
QSGAEVMKPGSSVKVSCKASGYTFSWYWLEWVRQAPGHGLEWMGEIDPGT
FTTNYNEKFKARVTFTADTSTSTAYMELSSLRSEDTAVYYCARFSHFSGSNYD
YFDYWGQGTLVTVSSGTGGSGGGGSGGGGSGGGASEIVMTQSPATLSVSPG
ERATLSCRASQSIGTNIHWYQQKPGQAPRLLIYYASESISGIPARFSGSGSGTEF
TLTISSLQSEDFAVYYCQQSWSWPTTFGGGTKVEIKENLYFQSGGSGHHHHH
HHH). The wild-type IgE-Fc3-4 with a VGEF signal sequence derived from the
pTTVH8G vector was cloned into pYD7 vector (NRC, Canada).
The ligelizumab scFv was co-expressed with the human IgE-Fc3-4 by co-
transfection in mammalian HEK 293-6E cells. A 1:1 mixture of plasmids was
transfected using linear polyethylenimine (PEI), 25 KD (Polysciences) in a DNA:
PEI ratio of 1:3. The proteins were expressed for 100–120 h. After harvesting, the
cell supernatant was ﬁltered through a 0.45-μm ﬁlter (Millipore) and incubated
overnight at 4 °C with Ni-NTA resin (Qiagen), washed with wash buffer (50 mM
Tris pH 8.0, 300 mM NaCl, 5 mM imidazole) and eluted with elution buffer
(50 mM Tris pH 8.0, 300 mM NaCl, 200 mM imidazole). Eluted protein complex
was concentrated using an Amicon Ultra-15 (Millipore) and puriﬁed with gel
ﬁltration on a Superdex 200 10/300 GL column (GE) using a running buffer
consisting of 20 mM Tris pH 8.0, 150 mM NaCl. His-tags were removed by
cleavage with TEV protease in the presence of 2.5 mM BME.
Crystallization and structure determination. Puriﬁed scFv:IgE-Fc3-4 complex
was concentrated to a ﬁnal concentration of 7.3 mg/ml in 20 mM Tris pH 8.0.
Crystallization was carried out using the hanging drop method, with a precipitant
composed of 0.2 M Na thiocyanate pH 6.9, 20% PEG3350 and 10 mM spermidine
as an additive. Crystals were obtained in 2–5 days at 14 °C. Crystals were harvested
and frozen in 0.2 M Na thiocyanate, 23% PEG 3350, 25% glycerol.
A complete diffraction dataset for the complex crystal was collected at 100° K at
the Advanced Photon Source at Argonne National Laboratories LS-CAT beamline
using an X-ray wavelength of 0.979 Å. The diffraction data were processed with X-
Ray Detector Software (XDS)51. The crystals belong to space group P212121
(Supplementary Table 2). The resolution limit of the data (3.65 Å) was set using an
I/sigma value of 1.3 Å and a CC1/2 value of 0.54. Molecular replacement was
carried out with Phenix Phaser52 using the structure of the IgE-Fc2-4 (Protein Data
Bank code: 2Y7Q53) as a search model for IgE and the scFv structure of the anti-
CD277 antibody 103.2 (Protein Data Bank code: 4F9P54) as a search model for
ligelizumab. Manual model building was carried out in Coot55 and reﬁnement was
done in Phenix Reﬁne52 using data from 3.65 to 20.0 Å. Model quality was
analyzed by Coot, and structure ﬁgures were generated using PyMol (Schrodinger,
LLC, New York). The ﬁnal model has Ramachandran statistics of 97.3% of residues
in the preferred region, 2.7% of the residues in the additionally allowed region and
no residues in the disallowed region. Additional reﬁnement statistics are collected
in Supplementary Table 2.
Protein interaction measurements with SPR. All SPR measurements were car-
ried out on a GE Healthcare Biacore X100 device (IL, USA). HBS-EP+ was used as
running buffer at a ﬂowrate of 10 μl/min. The target proteins were immobilized on
ﬂow cell 2 (Fc2) of a CM5 sensor chip by standard amine coupling. The sensor-
grams reﬂect binding responses on Fc2 minus binding responses on the reference
Fc1. To determine binding kinetics, we used the BIAevaluation software. Afﬁnity
constants were calculated using a 1:1 langmuir curve ﬁtting model.
To determine binding kinetics of ligelizumab and omalizumab antibodies/
fragments for human full-length IgE, 3000 RU of the anti-IgE Le27 were
immobilized on ﬂow cell 2 at pH 4.0. A concentration of 30 nM Sus11-IgE was
subsequently captured for 120 s to reach a response of ~100 RU. Various
concentrations (1.56–25 nM) of ligelizumab and omalizumab antibodies/fragments
were injected for 120 s and the dissociation was measured for 240 s under constant
buffer ﬂow. After each run, the chip surface was regenerated with 50 mM NaOH
and reloaded with Sus11-IgE.
To determine binding kinetics of ligelizumab and omalizumab IgG for wild-
type C328 and mutated C335 IgE-Fc3-4 variants, 100 RU of ligelizumab or
omalizumab IgG were immobilized on individual chips (ligelizumab: pH 5.0,
omalizumab: pH 4.5). A blank immobilization was performed on ﬂow cell 1.
Different concentrations (0.3–5 nM) of C328 and C335 IgE-Fc3-4 were injected for
120 s and the dissociation was measured for 180 s under constant buffer ﬂow. After
each run, the chip surface was regenerated with 10 mM glycine-HCl pH 2.0.
To assess whether ligelizumab or omalizumab IgG recognize FcεRIα:IgE
complexes, 1000 RU of recombinant human FcεRIα was immobilized on ﬂow cell 2
at pH 4.0. A blank immobilization was performed on ﬂow cell 1. A concentration
of 20 nM Sus11-IgE was subsequently captured for 120 s to reach a response of
>100 RU. Various concentrations (3.13–100 nM) of ligelizumab, omalizumab
antibodies/fragments and Le27 were injected for 120 s and the dissociation was
measured for 180 s under constant buffer ﬂow. After each run, the chip surface was
regenerated with 50 mM NaOH and reloaded with Sus11-IgE.
To assess whether ligelizumab or omalizumab IgG may disrupt FcεRIα:IgE
complexes, 1000 RU of recombinant human FcεRIα was immobilized on ﬂow cell 2
at pH 4.0. A blank immobilization was performed on ﬂow cell 1. A concentration
of 20 nM Sus11-IgE was subsequently captured for 120 s to reach a response > 100
RU. Three concentrations (0.25, 0.5 and 1 µM) of ligelizumab or omalizumab
antibodies/fragments were injected for 42 times 540 s with a dissociation time of
180 s between each injection under constant buffer ﬂow. At the end of each run the
chip surface was regenerated with 50 mM NaOH and reloaded with Sus11-IgE.
To assess whether ligelizumab or omalizumab IgG may disrupt FcεRIα:IgE-Fc3-4
complexes, 1000 RU of recombinant human FcεRIα was immobilized on ﬂow cell 2
at pH 4.0. A blank immobilization was performed on ﬂow cell 1. A concentration of
20 nM IgE-Fc3-4 was subsequently captured for 120 s to reach a response > 100 RU.
Various concentrations (3.13–100 nM) of ligelizumab, omalizumab antibodies/
fragments and Le27 were injected for 120 s and the dissociation was measured for
180 s under constant buffer ﬂow. After each run, the chip surface was regenerated
with 50 mM NaOH and reloaded with IgE-Fc3-4.
To assess whether ligelizumab or omalizumab IgG interact with CD23:IgE
complexes, 3000 RU of recombinant human CD23 was immobilized on ﬂow cell 2
at pH 4.0. A blank immobilization was performed on ﬂow cell 1. A concentration
of 125 nM JW8-IgE was captured for 120 s to reach a response > 100 RU. Various
concentrations (31.25–500 nM) of ligelizumab, omalizumab antibodies were
injected for 120 s and the dissociation was measured for 180 s under constant
buffer ﬂow. After each run, the chip surface was regenerated with 50 mM NaOH
and reloaded with JW8-IgE. Ligelizumab and omalizumab IgG binding to
preformed CD23:IgE complexes was assessed using a polyclonal sheep anti-human
IgG antibody at 125 nM concentration (The Binding Site, Birmingham, UK).
Protein interaction measurements with ELISA. To measure the binding inter-
action of ligelizumab or omalizumab with human IgE, the anti-IgE antibodies were
immobilized on plastic surface of a 96-half-well plate (Corning, NY, USA) at a
concentration of 30 nM by overnight incubation in PBS at 4 °C. The next day, the
plate was blocked with PBS/0.15% casein for 2 h at room temperature (RT) and
washed with PBS/0.05% Tween. Human Sus11-IgE was incubated at a serial
dilution (0.03–7.5 nM) for 1 h at RT. The plate was washed two times with PBS/
0.05% Tween and incubated for 1 h with the same wash buffer followed by three
times washing with PBS only. IgE was detected with monoclonal non-competitive
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anti-IgE Le27 coupled to horseradish-peroxidase (HRP). TMB (3,3′,5,5′-tetra-
methylbenzidine, Merck, Darmstadt, Germany) was used as a substrate for HRP
and the reaction was stopped with 1M sulfuric acid. Absorbance was measured at
450 nm wavelength using the standard ELISA reader SpectraMax M5 from
Molecular Device LLC (San Jose, CA, USA).
To measure the binding interaction of ligelizumab or omalizumab with wild-
type C328 and mutated C335 IgE-Fc3-4 variants, the anti-IgE antibodies were
immobilized on plastic surface of a 96-half-well plate (Corning, NY, USA) at a
concentration of 10 nM by overnight incubation in PBS at 4 °C. The next day, the
plate was blocked with PBS/0.15% casein for 2 h at RT and washed with PBS/0.05%
Tween. Wild-type C328 and mutated C335 IgE-Fc3-4 variants were incubated at a
serial dilution (0.0001–10 nM) for 1 h at RT and subsequently washed with PBS/
0.05% Tween and PBS. Development of the assay was performed as
mentioned above.
To measure IgE-binding to FcεRI, we immobilized recombinant human FcεRIα
on a plastic surface of a 96-half-well plate (Corning, NY, USA) at 30 nM by
overnight incubation in PBS at 4 °C. The next day, the plate was blocked with PBS/
0.15% casein for 2 h at RT. Biotinylated JW8-IgE was incubatd at a 1:3 serial
dilution (60–0.001 nM) for 1 h at RT. IgE-binding was detected with poly-HRP-
conjugated streptavidin (Thermo Scientiﬁc, Waltham, MA, USA) and was followed
by development with TMB.
To assess the inhibition of IgE-binding to FcεRIα by ligelizumab and
omalizumab, we immobilized recombinant human FcεRIα on plastic surface of a
96-half-well plate (Corning, NY, USA) at a concentration of 30 nM by overnight
incubation in PBS at 4 °C. The next day, the plate was blocked with PBS/0.15%
casein. Anti-IgE antibodies (0.0078–600 nM) were pre-incubated with biotinylated
JW8-IgE (0.78 nM) for 30 min at RT and were added for 1 h to the plate. The plate
was washed with PBS/0.05% Tween and PBS. IgE binding was detected with poly-
HRP-conjugated streptavidin and was followed by development with TMB.
For the CD23-binding ELISA, we immobilized 60 nM recombinant human
CD23 (R&D Systems, Minneapolis, MA, USA) on a 96-half-well plate (Corning,
NY, USA) by overnight incubation at 4 °C. The following day, the plate was
blocked with PBS/0.15% casein. The JW8-IgE was mixed 1:1 with NIP7-BSA
(Biosearch Technologies, Petaluma, CA, USA) in PBS/0.15% casein at a 1:2 serial
dilution (280–2.1875 nM) and incubated for 30 min at RT. The IgE-antigen
complexes were then incubated on the plate for 1 h at RT. IgE binding was detected
with biotinylated anti-IgE antibody Le27 (2.66 μg/ml) and poly-HRP-conjugated
streptavidin followed by development with TMB. In the inhibition ELISA for
CD23-binding IgE-antigen complexes (70 nM:70 nM) were incubated with a
1:2 serial dilution of the anti-IgE antibodies (280–0.5469 nM) for 30 min at RT
before incubation on the ELISA plate.
Protein interaction measurements on cells. Primary human basophils and
BDCA1+ DCs were isolated from whole-blood donations. Human peripheral
whole-blood was obtained from volunteering donors, who provided informed
consent in accordance with the Helsinki Declaration. The study was approved
by the local ethics committee (KEK 2018-00204). Basophils and BDCA1+ DCs
were enriched by Percoll density centrifugation of dextran-sedimented super-
natants. Furthermore, basophils were puriﬁed with negative selection using the
Milteny basophil isolation kit II (Miltenyi Biotec, Bergisch Gladbach, Germany).
BDCA1+ DCs were isolated with positive selection using the Milteny human CD1s
(BDCA-1+ dendritic cell isolation kit (Miltenyi Biotec, Bergisch)). Cells were
analyzed for purity via ﬂow cytometry.
To compare the efﬁcacy of ligelizumab and omalizumab IgG to inhibit IgE
binding to FcεRIα expressing cells, we cultured isolated primary human basophils
at a density of 1 × 106 cells/ml per well in a 96-well round-bottom plate (Falcon,
Tewksbury, MA, USA). First, we removed endogenous IgE from the cell surface by
addition of 5 µM of the disruptive anti-IgE DARPin® protein bi53_79 in RPMI+/+
supplemented with 10 ng/ml recombinant human IL-3 overnight for basophils. The
next day, the cells were washed and incubated with different concentrations of
JW8-IgE (0.006–100 nM) to assess dose-dependent binding. The concentration of
2 nM was further used for inhibition experiments with anti-IgE antibodies. JW8-
IgE was pre-incubated with increasing concentrations (0.032–100 nM) of
ligelizumab or omalizumab for 30 min at RT. Surface IgE was stained and
quantiﬁed by ﬂow cytometry 1 h after adding this mix to the cells. To assess the
inhibition proﬁle of ligelizumab and omalizumab IgG to inhibit IgE binding to
FcεRIα BDCA-1+ DCs without the presence of any additionally cytokines or
growth factors, we modiﬁed the protocol above and removed the endogenouse
IgE from the cells by the disruptive anti-IgE DARPin® protein bi53_79 only in
RPMI+/+ medium during an incubation of 4 h. Subsequently, the cells were
washed and incubated with different concentrations of JW8-IgE (100–0.005 nM) to
assess dose-dependent binding. The concentration of 25 nM JW8–IgE was further
used for inhibition experiments with anti-IgE antibodies. JW8-IgE was pre-
incubated with increasing concentrations (0.0012–312.5 nM) of ligelizumab or
omalizumab for 30 min at RT. Surface IgE was stained and quantiﬁed by ﬂow
cytometry 1 h after adding this mix to the cells. Surface IgE was stained and
quantiﬁed by ﬂow cytometry 1 h after adding this mix to the cells.
To assess inhibition of IgE-dependent basophil activation, we ﬁrst determined
the concentration of JW8-IgE to be used to reach half-maximal activation. For this
we titrated JW8-IgE (0.0064–20 nM) on 25,000 anti-IgE DARPin® protein-treated
human primary basophils and subsequently stimulated these cells with 100 ng/mL
NIP7-BSA (Biosearch Technologies, Petaluma, CA, USA) in RPMI+/+-containing
human 10 ng/ml recombinant human IL-3 and Flow CAST® kit antibody staining
mix (Bühlmann Laboratories AG, Schönenbuch, CH). The concentration of 0.68
nM JW8-IgE was subsequently used for pre-incubation with increasing
concentrations (0.0064–20 nM) of ligelizumab and omalizumab in RPMI+/+
medium for 30 min at RT. Anti-IgE DARPin® protein-treated primary human
basophils were then sensitized for 2 h at 37 °C with this mixture and stimulated
with 100 ng/mL NIP7-BSA. Activation was determined by measuring CD63+
basophils using ﬂow cytometry.
To investigate whether anti-IgE antibodies might actively remove FcεRIα-
bound IgE from the cell surface, we cultured 50,000 isolated primary human
basophils (1 × 106 cells/ml) with either 0, 0.25, 0.5 or 1 µM of ligelizumab or
omalizumab antibodies/fragments in RPMI+/+ supplemented with 10 ng/ml
recombinant human IL-3. After 3 and 6 days of culture, the cells were stained with
anti-IgE antibody for 15 min at RT and measured by ﬂow cytometry.
The human RPMI8866 leukemia B-cell line was kindly provided by Dr.
Monique Vogel. The cells were cultured in RPMI+/+ medium at a density of 2.5 ×
105 cells/ml in a 250-ml cell culture ﬂask (Greiner Bio One, Kremsmünster, AUT).
One day before the experiment, the cells were split 1:2 in RPMI+/+ medium. Flow
cytometry was performed using a BD FACSCanto device (BD Bioscience, Franklin
Lakes, NJ, USA) and results were evaluated with FlowJo Version 10.1 (Ashland,
OR, USA).
To assess whether ligelizumab accelerates dissociation of FcεRI-bound IgE-Fc3-4
on puriﬁed primary human basophils (purity > 90%), endogenous IgE was removed
from 50,000 basophils per well by incubation with 5 µM disruptive anti-IgE
DARPin® protein bi53_79 in RPMI+/+. After washing with PBS pH 7.4, the cells
were reloaded with 100 nM JW8-IgE or C328 IgE-Fc3-4. Again the cells were
washed with PBS pH 7.4. Then the cells were treated with 0.6–66.6 nM ligelizumab
or omalizumab IgG in RPMI+/+ medium containing human 10 ng/ml
recombinant human IL-3 for 30 min at 37 °C and 5 % CO2. Surface expression of
human IgE was determined with an anti-human IgE FITC antibody and basophil
activation was assessed using the Flow CAST® kit (Bühlmann Laboratories AG) by
ﬂow cytometry.
For IgE titration on CD23 expressing cells, 5 × 104 RPMI8866 cells per well
were seeded in a 96-well plate (Corning, NY, USA) and incubated with biotinylated
JW8-IgE for 1 h at 37 °C, 5% CO2 in RPMI+/+ medium. Subsequently, the cells
were stained with streptavidin FITC (Invitrogen, Carlsbad, CA, USA), anti-CD23
and anti-CD19 antibodies for 20 min at 4 °C. For the IgE inhibition on CD23
expressing cells, 12.5 nM biotinylated JW8-IgE was pre-complexed with the anti-
IgE antibodies (0.01–25 nM, 1:2 serial dilution) in RPMI+/+ medium for 30 min at
RT. Subsequently, this mix was added to the RPMI8866 cells for 1 h at 37 °C, 5%
CO2 in RPMI+/+ medium. Staining was performed as mentioned above.
To check for binding of anti-IgE antibodies to CD23-bound IgE RPMI8866 cells
were incubated with 12.5 nM biotinylated JW8-IgE for 1 h at 37 °C, 5% CO2 in
RPMI+/+ medium. The cells were then washed three times with 150 μl of PBS pH
7.4 and centrifuged at 600 × g for 5 min at 4 °C, resuspended in RPMI+/+ medium
containing 12.5 nM ligelizumab, omalizumab or control IgG and incubated for 30
min at 37 °C. Subsequently, the cells were washed two times with 200 μl of PBS pH
7.4 and stained with streptavidin, anti-CD19 and monoclonal mouse anti-human
Ig κ light chain (clone TB28-2, Thermo Fisher Scientiﬁc, MA, USA) at 4 °C.
Blocking of CD23 receptor was performed by incubation of the RPMI8866 cells
with 5 nM anti-CD23 DARPin® protein D89_86 (ref. 44) for 15 min at 37 °C, 5%
CO2. Cells were then washed once with PBS before incubation with JW8-IgE and
the anti-IgE antibodies as described above.
To assess the effect of ligelizumab and omalizumab on IgE:antigen complex
internalization with BDCA1+ DCs, we conjugated pH-sensitive rodamine (pH-
Rodo) to NIP-speciﬁc JW8 IgE by the pHrodo Red Microscale Labeling Kit (Life
Technologies). The ﬂuorophore pH-Rodo increases emission at more acidic pH),
which happens along the pathway of endocytosis/phagocytosis (i.e. endosomal/
lysosomal pH range from pH 6 to 4.5). First pH-Rodo IgE:antigen complexes were
formulated with 25 nM pH-rodo IgE and 2.5 nM NIP(15)BSA (Biosearch
Technologies, Petaluma, California, USA) for 0.5 h at RT and were then
supplemented with an 5 nM ligelizumab or omalizumab for additional 0.5 h at RT.
Upon removing the endogenous IgE from basophils and BDCA1+ DCs by the
disruptive anti-IgE DARPin® protein bi53_79 for 4 h at 37 °C, the cells were
washed and pulsed with formulated IgE:antigen:anti-IgE antigen complexes for 2 h
at 37 °C. After pulsing the cells, the cells were washed intensively and further
incubated time-dependently (i.e. 4 h, 8 h, 12 h, 16 h) at 37 °C. The pH-Rodo JW8-
IgE emissions were ﬁnally measured in the PE-channel by ﬂow-cytometry.
To assess the binding of anti-IgE antibodies to CD23-bound IgE by
multispectral imaging ﬂow cytometry, RPMI8866 cells were diluted to 1 × 106 cells/
ml, and 1 × 105 cells per well were seeded in a 96-well round-bottom plate.
Washing was performed once with 200 µl of PBS pH 7.4 at 500 × g for 5 min at
4 °C. The cells were then resuspended in 100 µl of RPMI+/+ medium containing
12.5 nM biotinylated JW8-IgE and incubated for 1 h at 37 °C, 5% CO2. Afterward,
the cells were washed three times with 200 µl of PBS pH 7.4 at 500 × g for 5 min at
4 °C, followed by 30 min incubation at 37 °C, 5% CO2 in 100 µl of RPMI+/+
medium containing 12.5 nM ligelizumab, omalizumab or isotype IgG.
Subsequently, the cells were stained with anti-CD23, anti-Ig κ light chain and
streptavidin antibodies for 20 min at 4 °C. Binding of IgE and the anti-IgE
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antibodies was assessed using an Amnis® ImageStream®X MKII and the
corresponding IDEAS® software (Luminex corporation, Austin, TX, USA).
IgE ELISpot and culture supernatants. Peripheral blood mononuclear cells were
isolated from fresh whole blood supplemented with 100 mM EDTA using Ficoll
Paque PLUS (GE Healthcare, Chicago, IL, USA) density gradient centrifugation.
The blood was diluted 1:2 in PBMC wash buffer (PBS pH 7.4 complemented with
2% FCS, 2 mM EDTA), overlaid onto Ficoll layer and centrifuged at 1800 rpm for
35 min at RT with brakes off. The peripheral blood leukocyte (PBL) layer was
extracted and washed with PBMC wash buffer at 1200 rpm for 5 min, followed by
two times washing with PBS pH 7.4 at 1000 rpm for 10 min.
A total of 2.5 × 105 PBMCs were cultured in 96-well round-bottom plates at a
density of 1 × 106 cells/ml in RPMI+/+ medium. The cells were stimulated with 30
ng/ml recombinant human IL 4 and 1 μg/ml anti-human CD40 antibody for 6 days
at 37 °C, 5% CO2 in the presence of 0.5 μM anti-IgE antibodies. Unstimulated,
untreated and monoclonal anti-human IgG1 antibody-treated cells served as
controls. For the detection of IgE-producing B-cells, we used 96-well MultiScreen
ﬁlter plates (Merck Milipore, Burlington, MA, USA) and the human IgE
ELISpotBASIC kit (Mabtech, Nacka Strand, Sweden). Overnight incubation of the
coating antibody (15 μg/ml) at 4 °C was followed by blocking for 2 h with RPMI+/+
medium the next day. The PBMCs were washed twice with PBS pH 7.4 before
transfer to a MultiScreen plate and incubation in RPMI+/+medium complemented
with recombinant human IL-4 (30 ng/ml) and anti-CD40 (1 μg/ml) for 24 hours at
37 °C, 5% CO2. For IgE detection, Mabtech detection antibody mixture (1 μg/ml,
5 h) and poly-HRP-conjugated streptavidin (0.17 µg/ml, 30 min) were diluted in
RPMI+/+ medium and incubated on ELISA plate shaker at RT. For HRP substrate,
we used the AEC staining kit (Sigma, Kawasaki, Kanagawa, Japan) and incubated
the plate with 50 μl per well for 5 min. The colorimetric reaction was stopped by
washing the plate with ddH2O. Washing steps were performed with PBS pH 7.4 or
PBS pH 7.4/0.05% Tween. Spots were quantiﬁed using an ELISpot reader and the
corresponding iSpot software v7.0 (AID GmbH, Strassberg, Germany).
To assess the effect of anti-IgE antibodies on the production of soluble IgE, we
cultured PBMCs at 1 × 106 cells/ml in RPMI+/+ medium at 37 °C, 5% CO2 in the
presence of 0.5 µM anti-IgE antibodies and 0.5 µM of the anti-FcγRIIB DARPin®
protein D11 (ref. 56), respectively. IgE production was induced by stimulation with
30 ng/ml recombinant human IL-4 and 1 μg/ml anti-human CD40 antibody for
12 days. On day 12, the supernatants were collected and soluble IgE was measured
by ELISA. For the ELISA, anti-IgE antibody Le27 was immobilized on plastic
surface of a 96-half-well plate (Corning, NY, USA) at a concentration of 30 nM by
overnight incubation in PBS at 4 °C. The next day, the plate was blocked with PBS/
0.15% casein. The culture supernatants were incubated for 1 h on the plate followed
by washing twice with PBS pH 7.4 or PBS pH 7.4/0.05% Tween. IgE was detected
using Mabtech detection antibody mixture (1 μg/ml, 1 hour) and poly-HRP-
conjugated streptavidin (0.17 µg/ml, 30 min) diluted in PBS/0.15% casein and
incubated on ELISA plate shaker at RT. TMB (Merck, Darmstadt, Germany) was
used as a substrate for HRP and the reaction was stopped with 1M sulfuric acid.
Absorbance was measured at 450 nm wavelength using the standard ELISA reader
SpectraMax M5 from Molecular Device LLC (San Jose, CA, USA).
In vivo passive systemic anaphylaxis. Mice transgenic for human FcεRIα
(huFcεRIα tg) on a mixed C57BL/6J–C57BL/6N background were obtained from
Prof. J.-P. Kinet. All animal experimentation was approved by the local ethics
committee (authorization BE66/18). Seven days before the experiment, huFcεRIα
tg mice were subcutaneously implanted with an electronic temperature transpon-
der (IPTT-300) from BMDS (Delaware, USA) to measure body-core temperature
as instructed by the manufacturer. On day 0, mice received an intraperitoneal
injection of PBS or 20 µg of anti-IgE antibody (ligelizumab or omalizumab in
200 µl). Half an hour later, mice were passively sensitized with 20 μg of NIP-speciﬁc
human JW8-IgE (in 200 µl) by intraperitoneal injection. On day 1, mice were
challenged by intraperitoneal injection of 200 μg of NIP20-BSA (Biosearch Tech-
nologies, Petaluma, CA, USA). Body-core temperature was measured before
challenge (baseline) and every 10 min after antigen-challenge for 60 min and every
30 min until 120 min. Data are represented as measured temperature after chal-
lenge minus baseline temperature (Δ core body temperature) for each time point.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.
Data availability
Coordinates of the IgE-Fc:ligelizumab-scFv complex structure have been deposited to the
Protein Data Bank (PDB) under accession number 6UQR (https://doi.org/10.2210/
pdb6uqr/pdb). Structural information about FcεRIα:IgE-Fc2-4 (PDB ID: 2Y7Q (https://
doi.org/10.2210/pdb2Y7Q/pdb)53), CD23:IgE-Fc2-4 (PDB ID: 4EZM (https://doi.org/
10.2210/pdb4EZM/pdb)57) and Omalizumab-Fab:IgE-Fc3-4 (PDB ID: 5HYS (https://doi.
org/10.2210/pdb5HYS/pdb)41) complexes are accessible in the Protein Data Bank (PDB).
Raw data for Figs. 1, 2, 3, 4, 5, and Supplementary Figs. 1, 2, 3, 5 are provided in the
Source Data ﬁle. All other data are available from the corresponding authors upon
request.
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